Bristol-Myers Squibb (BMY) Reports Strong Multiple Myeloma Data

Bristol-Myers Squibb Company (NYSE:BMY) ranks among the top picks for a retirement portfolio. Bristol-Myers Squibb Company (NYSE:BMY) reported on September 23 that its Phase 3 EXCALIBER-RRMM trial using iberdomide combined with daratumumab and dexamethasone showed strong improvement in minimal residual disease negativity rates among individuals with relapsed or refractory multiple myeloma.

Iberdomide belongs to a new class of drugs known as cereblon E3 ligase modulators (CELMoDs), which capitalize on Bristol Myers Squibb’s expertise in controlled degradation of proteins.

According to the company, the trial will proceed according to plan to assess the other dual-primary objective of progression-free survival, as well as crucial secondary endpoints like survival rate and safety.

A multinational biopharmaceutical corporation, Bristol-Myers Squibb Company (NYSE:BMY) is engaged in product discovery, research, licensing, manufacturing, marketing, and distribution.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.